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1Division of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo,
JapanIntroduction: Obesity-related glomerulopathy is an established secondary glomerular disease that may
occur in obese individuals with a body mass index (BMI) of $30 kg/m2. However, patients with moderate
obesity (BMI # 30 kg/m2) may also develop this disease.
Methods: A total of 20 patients with grade 1 obesity (25 # BMI < 30 kg/m2) with persistent proteinuria,
without evidence of other renal diseases, were analyzed retrospectively. These patients were compared
with 20 patients with grade 2 or higher obesity (BMI $ 30 kg/m2) with persistent proteinuria. Biopsies of 31
kidney transplant donors as healthy controls were used to compare histologic parameters.
Results: Similar to the grade 2 or higher obesity group, the grade 1 obesity group had a male predomi-
nance (85%) and showed a high incidence of hypertension (80%). Urinary protein excretion and renal
outcome parameters were comparable between the groups. Patients with grade 1 obesity showed typical
histologic features of obesity-related glomerulopathy: low glomerular density with glomerulomegaly. The
glomerular density and mean glomerular volume in the grade 1 group, the grade 2 or higher group, and
the kidney transplant donors with grade 1 obesity were 1.6  0.8 versus 1.4  0.6 versus 3.0  1.1 (per
mm2) and 6.1  2.1 versus 6.4  1.6 versus 2.9  0.8 (106 mm3), respectively.
Discussion: A glomerulopathy similar to obesity-related glomerulopathy can occur in moderately obese
individuals. Renal factor(s), such as low glomerular density, may thus underlie susceptibility to this
disease entity as well as BMI.
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CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).O besity-related glomerulopathy (ORG) is an estab-lished disease entity that occurs in obese in-
dividuals. Kambham et al.1 reported an increased
incidence of ORG among patients subjected to kidney
biopsy in the United States. In that study, the number
of ORG cases increased from 0.2% in 1986–1990 to
2.0% in 1996–2000. Likewise, reports from Spain,
China, and Japan have suggested that the incidence of
ORG is increasing, likely due to the increasing rates of
obesity in the general population.2–4
ORG is deﬁned as a proteinuric renal disease in pa-
tients with a body mass index (BMI) of $30 kg/m2 and
without clinical and histopathologic evidence of other
renal diseases.1,2,4 The typical clinical features of ORGspondence: Nobuo Tsuboi, Division of Nephrology and
tension, Department of Internal Medicine, The Jikei Univer-
chool of Medicine, 3-25-8 Nishi-Shinbashi, Minato-Ku, Tokyo,
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ved 22 May 2016; revised 17 July 2016; accepted 7 August
published online 12 August 2016include moderate or massive amounts of proteinuria
without a decrease in serum levels of albumin.1–4
Histopathologically, glomerulomegaly, and focal
segmental glomerulosclerosis (FSGS) are characteristic
ﬁndings,1,2,4 likely reﬂecting intraglomerular hyper-
ﬁltration in these patients.5–7 Moreover, the glomerular
density (glomerular number per renal cortical area of a
needle biopsy) is extremely low in patients with ORG.8
Such an uneven glomerular density distribution in
patients with ORG is unlike that in biopsies of kidney
transplant donors and patients with other primary
glomerular diseases. In addition, an autopsy analysis of
the glomerular density in nondiseased kidneys sug-
gested that such a low glomerular density is present
only in patients with ORG, and is rare in individuals
with a BMI $30 kg/m2 in the absence of renal disease.
Despite the marked glomerulomegaly in patients with
ORG, the glomerular volume in kidneys of obese in-
dividuals without renal disease is only slightly greater.
These results suggest that a low glomerular density
associated with glomerulomegaly is a characteristicKidney International Reports (2016) 1, 250–255
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this difference in histopathologic measures is not sim-
ply related to BMI.
In a survey of the Japanese population, moderate
obesity (25 # BMI < 30 kg/m2) was closely related to
an increased incidence of various obesity-related dis-
eases, and so this BMI category was deﬁned as grade 1
obesity.9 Recent epidemiologic studies suggest that a
substantial number of patients have a disease state
similar to ORG, including those with grade 1
obesity.10–12 Currently, however, little is known
regarding the renal complication(s) that can occur in
patients in this BMI category. In the current study, we
explored the clinicopathologic characteristics of a
proteinuric renal disease in moderately obese subjects
in whom renal biopsy was performed.
METHODS
Patients
This study included patients who underwent renal bi-
opsies of native kidneys at Jikei Hospital, Tokyo, from
1999 to 2008. The exclusion criteria are shown in Table 1.
Patients with renal manifestations, including renal
impairment or proteinuria, before becoming obese and
thosewho showed acute-onset nephrotic syndromewere
excluded. Impaired glucose tolerance alone, as deﬁned as
an HbA1c $ 6.5% at the time of biopsy, was not a cri-
terion for exclusion. However, patients with a history of
impaired glucose tolerance for >5 years or those with
extrarenal diabetic complications, including retinop-
athy and neuropathy, were excluded from this study.
Glomerular injuries in patients with obesity were
deﬁned morphologically as obesity-associated glomer-
ulomegaly with or without FSGS lesions, as reported
previously.1–4,8 Patients whose renal biopsies showed
clinical and histologic evidence of other primary
or secondary renal diseases, including diabetic ne-
phropathy, were excluded. Increased glomerular base-
ment membrane thickness alone was not a criterion for
exclusion, because obese patients can exhibit an
increased glomerular basement membrane thickness in
the absence of diabetes.13,14 Likewise, the presence ofTable 1. The exclusion criteria
Patients who were excluded from the study
(1) Renal impairment or proteinuria before becoming obese
(2) Sudden onset of nephrotic syndrome
(3) Glucose intolerance for more than 5 yr
(4) Extrarenal manifestations of diabetes
(5) Any other glomerular disease including diabetic nephropathy
(6) Moderate-to-severe hypertensive nephrosclerosis
(7) Less than 2-yr follow-up
Not excluded
(1) Hypertension without moderate-to-severe hypertensive nephrosclerosis
(2) Thickened GBMs alone
GBM, glomerular basement membrane.
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specimens of some obese hypertensive patients had
moderate-to-severe vascular lesions, which were
accompanied by collapsed glomeruli. Patients with such
histologic features were diagnosed with hypertensive
nephrosclerosis instead of glomerulopathy associated
with obesity, and were excluded from this study.
Patients with at least 2 years of follow-up data were
included in this study.
Deﬁnitions
According to the criteria proposed by the Japan Society
for the Study of Obesity, grade 1 obesity was deﬁned as
25# BMI < 30 kg/m2, grade 2 as 30# BMI < 35 kg/m2,
grade 3 as 35 # BMI < 40 kg/m2, and grade 4 as a
BMI $ 40 kg/m2.15 The biopsies of 20 patients with
grade 1 obesity (group 1) and 20 patients with grade 2
or higher obesity (group 2; 16 with grade 2 and 4 with
grade 3) were recruited from the renal biopsy archive
during the study period. Renal biopsies of kidney
transplant donors without apparent chronic kidney
diseases were used for comparisons of histologic ﬁnd-
ings. Of these kidney transplant donors, 21 cases had a
BMI of < 25 kg/m2 and 10 had a grade 1 obesity. The
estimated glomerular ﬁltration rate (eGFR) was calcu-
lated using a modiﬁed 3-variable equation for the GFR
of Japanese individuals:16 eGFR ¼ 194  age–0.287 
sCr–1.094 (0.739 if female), where sCr is the serum level
of creatinine. Hypertension was deﬁned as a systolic
blood pressure > 140 mm Hg and/or diastolic blood
pressure > 90 mm Hg, or use of antihypertensive
medications. Subjects using antihypertensive medica-
tions, such as angiotensin blockers, for the purpose of
renoprotection despite a normal blood pressure were
considered to be normotensive.
Pathologic Analysis
Renal specimens were obtained by percutaneous needle
biopsy. Renal biopsies of kidney transplant donors were
performed under direct vision using a needle biopsy
gun. Renal biopsy specimens obtained 1 hour after renal
transplantation were used for the analyses. An 18-gauge
biopsy needle was used in all cases. The tissues were
embedded in parafﬁn, cut into 3- to 4-mm sections and
stained with hematoxylin and eosin, periodic acid-
Schiff, Masson’s trichrome, and periodic acid methe-
namine silver. All biopsy specimens were subjected to
immunohistochemical and electron microscopy ana-
lyses. The area of interstitial ﬁbrosis and/or tubular
atrophy was evaluated semiquantitatively according to
the proportion of cortical area involvement. The grade
of arterial lesions was scored according to the most se-
vere lesion within the specimen, and intimal thickening
was scored by comparing the thickness of the intima251
Table 2. Comparison of clinical characteristics at the time of biopsy
Variables
Grade 1
obesity,
n [ 20
Grade 2 or
higher obesity,
n [ 20
P value, grade 1
versus grade 2
or higher
Age 52  11 45  14 0.073
Gender (%male) 85 80 0.677
BMI (kg/m2) 26.9  1.3 32.0  2.4 –
Hypertension (%) 80 70 0.465
Serum creatinine (mg/dl) 1.1  0.5 1.2  0.7 0.812
eGFR (ml/min per 1.73 m2) 59  20 64  31 0.545
Urinary protein excretion (g/d) 2.1  1.5 2.0  1.8 0.800
Serum albumin (g/dl) 4.3  0.3 4.3  0.3 0.924
Serum uric acid (mg/dl) 7.3  1.6 7.5  1.8 0.698
Serum total cholesterol (mg/dl) 237  35 216  37 0.073
Serum triglyceride (mg/dl) 282  205 223  122 0.273
Hemoglobin A1c (%) 5.9  0.5 5.9  0.5 0.676
BMI; body mass index, eGFR; estimated glomerular ﬁltration rate.
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deﬁned the severity of arterial lesions lacking intimal
thickening as grade 0, those with #50% intimal
thickening as grade 1, and those with>50% as grade 2.
The grade of arteriolar lesions was evaluated based on
the proportion of arterioles exhibiting hyalinosis as
follows: grade 0, <5% lesions; grade 1, 5% to 25%
lesions; and grade 2, >25% lesions. The percentage of
glomeruli affected by segmental or global sclerosis was
assessed. The variants of FSGS were determined for each
glomerulus according to a classiﬁcation previously re-
ported, including tip variant, collapsing variant,
cellular variant, perihilar variant, and not otherwise
speciﬁed.17 The glomerular density was determined by
calculating the number of glomeruli per total renal
cortical area, which was measured using a computerized
image analyzer (Leica IM500, Leica Microsystems,
Wetzlar, Germany). The measurement of glomerular
density is strongly inﬂuenced by the degree of global
sclerosis. Therefore, 2 deﬁnitions of glomerular density
were applied: the number of glomeruli that were not
globally sclerotic per total renal cortical area and the
number of glomeruli (including globally sclerotic
glomeruli) per total renal cortical area. The glomerular
area was deﬁned as the area described by the outer
capillary loops of the tuft using a computerized image
analyzer (Leica IM500, Leica Microsystems). The mean
glomerular area (GA) was calculated by averaging the
areas of all glomeruli. The mean glomerular volume (GV)
was calculated from the measured GA: GV ¼ (GA)3/2 
b/d, where b is a dimensionless shape coefﬁcient (b ¼
1.38 for spheres) and d is a size distribution coefﬁcient
used to adjust for variation in glomerular size.18 The
analysis used d ¼ 1.01, as in previous reports.19
Statistical Analysis
Continuous variables are expressed as means  SD. The
variables were assessed for normality both visually252(normal probability plot) and by inferential statistics
(Shapiro-Wilk W and Kolmogorov-Smirnov tests).
Continuous variables were compared by the t-test or
the Wilcoxon rank-sum test, as appropriate. Categorical
variables were expressed as percentages and compared
by the c2 test. Values of P < 0.05 were considered to
indicate statistical signiﬁcance. All statistical analyses
were performed using the SPSS software package
(SPSS, Chicago, IL).
RESULTS
Clinical Characteristics at the Time of Biopsy
The clinical characteristics at the time of biopsy of
patients with glomerulopathy associated with grade 1
and grade 2 or higher obesity are shown in Table 2.
Compared with group 2, those in group 1 tended to be
older. There was a male predominance in both groups,
with 80% in group 1 having hypertension. The serum
levels of creatinines and the mean eGFR values were
comparable between the groups. The mean serum
levels of albumin were comparable between the groups,
and no patients in either group had low concentrations.
The mean serum concentrations of uric acid, total
cholesterol, triglyceride, and HbA1c were comparable
between the groups.
Renal Outcomes
Renal outcome parameters were compared between the
patients with grade 1 and those with grade 2 or higher
obesity (Table 3). The average follow-up duration was
6.2 years in both groups. During the follow-up period,
angiotensin-converting enzyme inhibitors or angio-
tensin receptor blockers were used by 18 (90%) of the
patients in group 1 and 17 (85%) in group 2. No pa-
tients in either group received corticosteroids or
immunosuppressive reagents. The slopes of renal
function decline during the observation period
(DeGFR), and the frequencies of patients with a 30%
decrease in eGFR at the last observation, a 50%
decrease in eGFR at the last observation, and those who
developed end-stage renal disease were not signiﬁ-
cantly different between the groups.
Histopathologic Findings
The histopathologic ﬁndings are shown in Table 4.
Patients in group 1 had mild-to-moderate levels of
chronic renal injuries, including interstitial ﬁbrosis
and/or tubular atrophy, global glomerulosclerosis, and
FSGS. Among the renal biopsy specimens from these
patients, 21 glomeruli from 10 patients showed FSGS
lesions, 6 (29%) of which were perihilar variants and
the other 15 (71%) were of the not-otherwise-speciﬁed
variant. These features were similar to those in group 2.
Typical FSGS lesions showing cellular, collapsing, orKidney International Reports (2016) 1, 250–255
Table 3. Comparison of renal outcomea
Variables
Grade 1 obesity,
n [ 20
Grade 2 or higher
obesity, n [ 20 P value
Duration of follow-up (yr) 6.2  3.0 6.2  2.8 0.944
Use of ACE-I/ARB (%) 90 85 0.633
Use of corticosteroids or
immunosuppressants (%)
0 0 –
DeGFR (%/yr) 7.4  9.2 5.8  7.1 0.450
Patients with a 30% decrease
in eGFR at the last
observation (%)
50 40 0.525
Patients with a 50% decrease
in eGFR at the last observation
or those reached ESRD (%)
25 15 0.212
ACE-I, angiotensin-converting enzyme inhibitor; ARB; angiotensin receptor blocker;
eGFR, estimated glomerular ﬁltration rate; ESRD, end-stage renal disease.
aPatients with >2-yr follow-up were included in the analyses.
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Regarding vascular lesions, the mean grades of arterial
lesions and arteriole lesions were comparable.
The mean glomerular density and volume values
were compared between the groups. The glomerular
densities in both groups were considerably lower than
that of kidney transplant donors with or without
obesity. The low glomerular density in these obese
patients remained evident when globally sclerotic
glomeruli were included in the calculation of glomer-
ular density. In contrast, the glomerular volume of
these obese patients was markedly larger than that of
the kidney transplant donors with or without obesity.
The glomerular density and volume did not differ
signiﬁcantly between the 2 obesity groups. In addition,
they did not differ signiﬁcantly between the kidney
transplant donors with and without obesity.
Figure 1 shows the representative renal biopsy
ﬁndings in a case of kidney transplant donor (a) and aTable 4. Comparison of histopathologic ﬁndings
Variables
Grade 1 obesity,
n [ 20
Grade 2
obesity,
Interstitial ﬁbrosis and/or tubular atrophy (%) 28  21 27 
Glomeruli affected by global glomerulosclerosis (%) 22  17 25 
Patients with FSGS (%) 50 4
Glomeruli affected by FSGS (%) 6.2  8.1 5.2 
FSGS variant
Glomeruli with perihilar variant (%) 1.5  2.8 0.6 
Glomeruli with NOS variant (%) 4.5  6.3 4.6 
Glomeruli with cellular variant (%) 0
Glomeruli with collapsing variant (%) 0
Glomeruli with tip variant (%) 0
Arterial lesions (grade) 0.8  0.7 0.8 
Arteriole lesions (grade) 0.7  0.7 0.6 
Nonsclerosed glomerular number/total cortical area (per mm2) 1.6  0.8 1.4 
Total glomerular number/total cortical area (per mm2) 2.3  1.4 1.9 
Mean glomerular volume (106 mm3) 6.1  2.1 6.4 
FSGS, focal segmental glomerulosclerosis; NA, not assessed; NOS, not otherwise speciﬁed.
aGrade 1 obesity versus grade 2 or higher obesity.
bGrade 1 obesity versus kidney donor with grade 1 obesity.
Kidney International Reports (2016) 1, 250–255patient with glomerulopathy associated with grade 1
obesity (b). They are observed to be quite different
with regard to the density and the size of the glomeruli.
DISCUSSION
We explored the clinicopathologic characteristics of a
proteinuric glomerulopathy found in individuals with
grade 1 obesity (25 # BMI < 30 kg/m2). Our results
showed that the clinical characteristics of proteinuric
glomerulopathy in such patients were similar to those
in patients with grade 2 or higher obesity. In addition,
during an average of 6.2 years of follow-up, the renal
outcome parameters, including the slope of renal
function decline and the incidence of progression, did
not differ signiﬁcantly between the groups. Further-
more, the 2 groups exhibited similar histopathologic
ﬁndings. Notably, group 1 (grade 1 obesity) had typical
histologic characteristics of patients with ORG with a
BMI value of $30 kg/m2, that is, low glomerular
density with glomerulomegaly.
The glomerular density was extremely low in pro-
teinuric patients in both groups. Interestingly, such an
uneven distribution of glomerular density in these
obese patients was in sharp contrast to the widely
distributed glomerular density in biopsies of kidney
transplant donors with or without obesity, suggesting
that the difference was not simply related to BMI. In
addition, the low glomerular density in these obese
patients is not likely to be due to glomerular injury, as
indicated by the difference in glomerular density be-
tween the obese patients and kidney transplant donors,
even when globally sclerotic glomeruli were included
in the calculation of glomerular density. In addition,
the glomerular density in these obese patients wasor higher
n [ 20 P valuea
Kidney donor
(BMI < 25), n [ 21
Kidney donor grade 1
obesity, n [ 10 P valueb
20 0.921 5  4 9  8 0.003
20 0.715 5  7 4  6 <0.001
5 0.752 0 0 <0.001
7.6 0.704 0 0 0.003
1.5 0.198 0 0 –
6.9 0.968 0 0 –
0 – 0 0 –
0 – 0 0 –
0 – 0 0 –
0.8 1.000 NA NA –
0.7 0.657 NA NA –
0.6 0.373 3.3  1.1 3.0  1.1 0.003
0.7 0.221 3.4  1.2 3.1  1.1 0.117
1.6 0.582 2.4  0.8 2.9  0.8 <0.001
253
Figure 1. Representative renal biopsy ﬁndings in light microscopy. The representative renal biopsy ﬁndings in (a) a case of a kidney transplant
donor (36-year-old normotensive man with the estimated glomerular ﬁltration rate [eGFR] of 109 ml/min per 1.73 m2 and the body mass index
[BMI] of 24.8 kg/m2) and (b) a patient with grade 1 obesity (42-year-old hypertensive woman with the eGFR of 81 ml/min per 1.73 m2 and the BMI
of 25.5 kg/m2) are shown. The arrows indicate nonsclerotic glomeruli. Periodic acid methenamine silver stain (original magnification 50).
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phropathy or membranous nephropathy who had
chronic renal injuries of similar severity.20,21 Finally,
hypertension may be associated with the low glomer-
ular density in obesity-associated glomerulopathy, as a
previous autopsy study showed a relationship between
essential hypertension and kidneys with a small num-
ber of nephrons.22 In fact, 80% of our patients in group
1 already had hypertension at the time of biopsy.
However, the glomerular density did not differ be-
tween normotensive grade 1 obesity patients and hy-
pertensive grade 1 obesity patients in the current series
(data not shown), suggesting that hypertension is un-
likely to be the only factor associated with the low
glomerular density in these patients.
Although the origin of glomerulomegaly in patients
with ORG is incompletely understood, several plausible
explanations for this typical morphologic feature of
ORG have been suggested. These include increased
sympathetic nerve activity and/or systemic blood
pressure, intraglomerular hypertension mediated by an
increase in salt reabsorption and vasodilation of the
afferent arterioles, and an increase in the number of
glomerular capillaries due to angiogenesis-promoting
factors.7,23–25 In addition to these obesity-associated
hemodynamic and humoral changes, a reduced total
number of nephrons may lead to glomerular enlarge-
ment in patients with ORG. Recent autopsy studies
have demonstrated a considerably greater variability in
the nephron number in the general population than
had been suspected.26–28 In addition, the number of
nephrons is correlated with birth weight, and low birth
weight, which is associated with an inappropriate in-
trauterine environment, is postulated to be a risk factor
for hypertension and progression of renal diseases in254later life.29,30 Therefore, glomerular hyperﬁltration may
be markedly greater in individuals born with a sub-
stantially reduced number of nephrons and who then
develop obesity. Together with the current results,
these ﬁndings support the possibility that, in addition
to obesity, renal factor(s) such as a reduced number of
total nephrons may underlie the susceptibility to renal
injuries associated with obesity.31 This notion is fully
consistent with the fact that the absolute risk of pro-
gressive renal deterioration in an obese individual is
low and only a minority of obese individuals actually
develop glomerular injury. However, whether the
glomerular density in a renal biopsy specimen repre-
sents the total number of nephrons in the kidney is
unclear, because data on the birth weight and total
cortical volume of the kidney were not available.
Therefore, the ﬁnding of a low glomerular density does
not demonstrate conclusively that the subjects had
a small number of glomeruli. Determining the origin
of the low glomerular density requires further
investigation.
A signiﬁcant proportion of the FSGS lesions in our
patients in each group were of the perihilar variant.
Other FSGS lesions found in these patients were of the
not-otherwise-speciﬁed variant; the other FSGS vari-
ants (the cellular, collapsing, and tip variants) were not
identiﬁed in this study. These results are consistent
with previous reports that FSGS lesions in patients
with ORG are mainly of the perihilar or not-otherwise-
speciﬁed variant, and other variants are identiﬁed only
rarely.1 However, the possibility remains that primary
FSGS occurred in the presence of obesity in our pa-
tients, as the cause of idiopathic FSGS is unclear and
idiopathic FSGS is diagnosed by the exclusion of FSGS
of secondary causes.17Kidney International Reports (2016) 1, 250–255
Y Okabayashi et al.: Proteinuria in Moderate Obesity CLINICAL RESEARCHIn conclusion, our ﬁndings suggest that the glo-
merulopathy in individuals with grade 1 obesity
without other known renal diseases is similar to that in
individuals with grade 2 or higher obesity in terms of
the clinicopathologic features. Therefore, a glomerul-
opathy similar to ORG can occur in moderately obese
subjects. Thus, renal factor(s) other than BMI may
underlie the susceptibility to this disease entity.
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